Recombinant viral vectors are disclosed that contain a nucleic acid encoding a Second Mitochondria-derived Activator of Caspases (Smac) protein inserted within an RNA virus genome, wherein the Smac protein specifically binds to at least a portion of an Inhibitor of Apoptosis Protein (IAP). Also disclosed are methods of treating cancer using the disclosed vectors.

A socket organizer for releasably and adjustably holding socket holders is provided. The organizer has a longitudinally extending rail assembly characterized by a generally U-shaped channel. A plurality of socket holders are positioned in and slidingly engage the channel. Each socket holder has a detent assembly for releasably locking a socket. A plurality of clip members are attached to the rail assembly or to mounting posts. The clip members have socket identification indicia and are positioned over the mounting posts by way of an aperture. A positioning mechanism is provided for selectively positioning individual socket holders in the channel.

The present disclosure provides materials and methods relating to recombinant viral expression vectors. In particular, the present disclosure provides novel recombinant viral expression vectors comprising an RNA virus backbone that encodes a virus capable of infecting a target organism and expressing a polynucleotide-of-interest in that target organism. The novel viral vector constructs provided herein are a versatile expression tool for interrogating gene function and an efficient delivery platform for gene editing technology.

The present invention pertains to a combination for simultaneous, separate or sequential use which comprises (a) an oncolytic virus and (b) a checkpoint inhibitor and to its use for the treatment of cancer.

The present disclosure provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a coronavirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a coronavirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present disclosure provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one coronavirus immunogenic glycoprotein fragment, as well as pharmaceutical compositions comprising the vaccine vectors.

The present invention pertains to a combination for simultaneous, separate or sequential use which comprises (a) an oncolytic virus and (b) a checkpoint inhibitor and to its use for the treatment of cancer.

Provided herein are chimeric pseudotyped recombinant RABV particles, wherein the chimeric envelope protein comprises, from N-terminus to C-terminus, a non-RABV envelope protein ectodomain, a non-RABV envelope protein transmembrane domain, and a RABV C-terminal domain. Also provided are methods for their use in delivering a transgene into a target cell.

The invention relates to a recombinant novirhabdovirus expressing a chimeric protein comprising the sequence of an antigen of interest flanked, at the N-terminus, by a signal peptide, and at the C-terminus, by a polypeptide comprising at least one portion of the transmembrane domain of a rhabdovirus G protein. Said recombinant novirhabdovirus can be used especially for inducing an immune response to the antigen of interest.

The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CD80 extracellular domain Fc-fusion protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.

The present disclosure provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a coronavirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a coronavirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present disclosure provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one coronavirus immunogenic glycoprotein fragment, as well as pharmaceutical compositions comprising the vaccine vectors.